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73.5% to 81.9% nucleotide sequence 
identity and from 90.1% to 96.9% 
amino acid sequence identity (Table). 
This level of sequence divergence, as 
well as the geographic speciﬁ  city of 
this hantavirus in French Guiana led 
us to provisionally name it Maripa 
virus.
Results of a serologic survey to 
identify cases of respiratory disease 
with no evident etiology led us to 
identify an HPS case-patient in French 
Guiana who had been infected with a 
new divergent hantavirus strain. Hu-
man hantavirus epidemics are associ-
ated with ﬂ  uctuations of rodent popu-
lations caused by climatic, ecologic 
and environmental changes or with 
changes in human activities associated 
with nature or agriculture. Therefore, 
in this region where 90% of the land is 
tropical rain forest but in which there 
is increasing economic development, 
continuous surveillance for the virus 
in the human population would be 
beneﬁ  cial. Surveys of potential reser-
voirs may help reduce the risk of viral 
emergence. 
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Fatal Human 
Case of West Nile 
Virus Disease, 
Mexico, 2009
To the Editor: West Nile virus 
(WNV; family Flaviviridae, genus 
Flavivirus) was ﬁ  rst recognized in the 
Western Hemisphere in 1999 during an 
outbreak of human, equine, and avian 
encephalitis in New York (1). The vi-
rus has since spread across the United 
States and Canada, where it has caused 
≈30,000 human infections and ≈1,000 
deaths. Serologic evidence has demon-
strated that WNV is present throughout 
Mexico, Central America, South Amer-
ica, and the Caribbean region (2–8). 
However, WNV illness in humans and 
vertebrate animals in these regions has 
been only sparsely reported. For in-
stance, 7 human cases of WNV infec-
tion have occurred in Mexico (exclud-
ing the case described here), 3 of which 
were severe. All patients survived. To 
our knowledge, no fatal human cases of 
WNV infection have occurred in Cen-
tral America, South America, or the 
Caribbean region.
We describe a fatal case of WNV 
infection in a human in Central Amer-
ica. The patient, a man 40 years of age, 
lived in Monterrey, Nuevo León State, 
in northern Mexico. He had not trav-
eled outside of the metropolitan area 
in the 6 months before illness onset. 
On June 11, 2009, inﬂ  uenza-like signs 
and symptoms (i.e., fever, malaise, 
fatigue, arthralgia, headache, and diz-
ziness) developed in the patient. On 
June 26, the signs and symptoms had 
not resolved, and the man was admit-
ted to University Hospital “Dr. José 
E. Gonzalez” at the Universidad Au-
tonoma de Nuevo León (UANL). At 
the time of admission, cerebrospinal 
ﬂ  uid (CSF) was collected, and labo-
ratory analysis indicated a markedly 
elevated leukocyte count (182 cells/
mm3; reference range 0–5 cells/mm3) 
and slightly elevated protein and glu-
cose levels.
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Several days later, serious neuro-
logic signs that included loss of con-
sciousness developed in the patient. 
On July 6, he lapsed into a coma and 
was transferred to the intensive care 
unit and treated for intracranial hy-
pertension. Another CSF specimen 
was collected, and laboratory ﬁ  nd-
ings demonstrated that the leukocyte 
count had increased to 495 cells/mm3. 
CSF cytologic examination showed 
atypical lymphocytes, some of which 
resembled plasma cells. Brain mag-
netic resonance imaging showed hy-
drocephalus with no brain parenchy-
mal lesions. Because the patient was 
suspected to have a herpes simplex 
virus infection, intravenous acyclovir 
was administered. Several days later, 
the patient showed signs of improve-
ment; on July 15, he was discharged. 
Eleven days later, he experienced se-
vere headaches and, on July 29, was 
readmitted to the UANL Hospital for 
intracranial hypertension. On July 30, 
a ventriculoperitoneal shunt was im-
planted; however, the patient’s condi-
tion continued to decline, and he died 
on August 1.
Personnel in the Laboratory of 
Molecular Infectology at the UANL 
were informed of the patient and were 
provided with the remainder of the 
second CSF specimen several days 
before his death. Total RNA and DNA 
were extracted from the CSF by using 
the QIAamp viral RNA extraction kit 
(QIAGEN, Valencia, CA, USA) and 
DNAzol (Invitrogen,  Carlsbad, CA, 
USA) and tested for nucleic acid to 
various pathogens associated with hu-
man central nervous system infections, 
speciﬁ  cally herpes simplex virus types 
1 and 2, human enterovirus A–D, den-
gue virus types 1–4, WNV, and Myco-
bacterium tuberculosis. Complemen-
tary DNA samples were generated 
by using Superscript III reverse tran-
scription (Invitrogen), and PCRs were 
performed by using Taq polymerase 
(Invitrogen) in accordance with the 
manufacturer’s instructions. PCR 
ampliﬁ  cations were conducted by us-
ing the following reaction conditions: 
94oC for 3 min; 30 cycles of 94oC for 
1 min, 50oC for 1 min, and 72oC for 
2 min; followed by a ﬁ  nal extension 
at 72oC for 8 min. Reverse transcrip-
tion–PCRs performed with diethyl 
pyrocarbonate–treated distilled water 
in place of nucleic acid were included 
as negative controls. All test and con-
trol reactions were performed in du-
plicate. PCR products were examined 
by 2% agarose gel electrophoresis and 
visualized with ethidium bromide. 
A PCR product of the expected size 
was observed when the WNV-spe-
ciﬁ  c  primers  WN-cap-F (5′-CAGT
GCTGGATCGATGGAGAG-3′) 
and WN-cap-R (5′-CCGCCGATTG
ATAGCACT GGT-3′) were used. 
These primers amplify a 104-nt re-
gion of the capsid gene. All other as-
say results were negative. Subsequent 
reactions were performed by using 
a second set of WNV-speciﬁ  c prim-
ers, WN-env-F (5′-GATGTGAAG
ATGATGAATATGG-3′) and WN-
env-R (5′-AATGCTTCCTTTGCCAA
ATAG-3′), which amplify a 216-nt 
region of the envelope gene. A PCR 
product of the expected size was again 
observed. PCR products were puriﬁ  ed 
by using the Purelink Gel Extraction 
Kit (Invitrogen) and sequenced by us-
ing a 3730×1 DNA sequencer (Applied 
Biosystems, Foster City, CA, USA).
Because of the small volume of 
CSF obtained, a comprehensive labo-
ratory analysis (virus isolation, plaque 
reduction neutralization test) could not 
be performed. Nevertheless, detection 
of WNV in the CSF of a patient with 
encephalitis meets the Centers for 
Disease Control and Prevention es-
tablished criteria for a case of West 
Nile neuroinvasive disease (9). Our 
ﬁ  ndings highlight the fact that the low 
number of WNV cases in Mexico and 
elsewhere in Latin America should not 
deter healthcare personnel from per-
forming WNV diagnostic testing and 
the public from using personal protec-
tive measures in these regions.
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Bartonella spp.
Infections, Thailand 
To the Editor:  Bartonella are 
fastidious hemotropic gram-negative 
bacteria with a worldwide distribu-
tion. In Thailand, Bartonella species 
have been demonstrated in mamma-
lian hosts, including rodents, cats and 
dogs, and in potential vectors, includ-
ing ﬂ  eas (1–4). However, data on hu-
man infection have been limited to case 
reports (5,6) and 1 seroprevalence sur-
vey, which found a 5.5% prevalence 
of past B. henselae infection (7). No 
studies have systematically assessed 
the frequency, clinical characteristics, 
or epidemiology of human Bartonella 
infections in Thailand.
We conducted a prospective 
study to determine causes of acute 
febrile illness in 4 community hospi-
tals, 2 in Chiang Rai (northern Thai-
land) and 2 in Khon Kaen (northeast-
ern Thailand). We enrolled patients 
>7 years of age with a temperature 
>38°C who were brought to study 
hospitals for treatment from Febru-
ary 4, 2002, through March 28, 2003. 
Patients were excluded if they had a 
history of fever for >2 weeks or an in-
fection that could be diagnosed clini-
cally. Acute-phase serum samples 
were collected at the time of enroll-
ment and convalescent-phase serum 
samples 3–5 weeks later. We enrolled 
nonfebrile control patients >14 years 
of age who had noninfectious con-
ditions; acute-phase serum samples 
were collected. Clinical information 
was abstracted from patient charts. 
Nurses conducted physical examina-
tions and personal interviews to col-
lect information on patients’ demo-
graphic characteristics, exposures to 
animals, and outdoor activities.
Serum samples were tested for 
immunoglobulin (Ig) G antibodies to 
Bartonella spp. by immunoﬂ  uorescent 
antibody assay at the Bartonella Labo-
ratory of the Centers for Disease Con-
trol and Prevention, Fort Collins, CO, 
USA. Strains used for antigen produc-
tion were: B. elizabethae (F9251), B. 
henselae (Houston-1), B. quintana 
(Fuller), and B. vinsonii subsp. vinsonii 
(Baker). Homologous hyperimmune 
serum specimens were produced in 
BALB/c mice as previously described 
(8). Bartonella infection was consid-
ered conﬁ  rmed in febrile patients who 
had a >4-fold rise in IgG antibody 
titers and a convalescent-phase titer 
>64. Probable infection was deﬁ  ned 
as 1) a 4-fold antibody titer rise but 
convalescent-phase titers of 64, or 2) 
high and stable titers (>512 in acute-
phase and convalescent-phase serum 
samples), or 3) acute-phase titer >512 
with a >4-fold titer fall. Paired serum 
samples from febrile patients were 
also tested for serologic evidence of 
other common causes of febrile illness 
in Southeast Asia.
Febrile patients with acute-phase 
and convalescent-phase IgG antibody 
titers <128 were considered not to have 
Bartonella infection; we compared 
demographic and clinical character-
istics of these patients to Bartonella-
infected patients. To evaluate potential 
risk factors, we compared Bartonella-
infected case-patients >14 years of age 
without serologic evidence of other in-
fections (n = 20) to nonfebrile controls 
with IgG to Bartonella <128 (n = 70). 
Age adjusted odds ratios (AORs) with 
95% conﬁ  dence intervals (CIs) were 
calculated.
Serologic testing was complet-
ed on paired serum samples for 336 
(46%) of 732 febrile patients en-
rolled; 92 (27%) had serologically 
conﬁ  rmed (50) or probable (42) Bar-
tonella infections. Thirty-ﬁ  ve (38%) 
of these 92 had serologic evidence of 
infection with another pathogen. The 
remaining 57 Bartonella-infected 
case-patients (34 conﬁ  rmed, 23 prob-
able) had a median age of 19 years 
(range 7–72 years); 65% were males, 
47% were students, and 35% were 
rice farmers. Common clinical char-
acteristics of Bartonella-infected pa-
tients included myalgias (83%), chills 
(79%), and headache (77%). Thirty 
(60%) patients had anemia (hemoglo-
bin level <13 mg/dL); 18 (32%) had 
a hemoglobin level <12 mg/dL, and 
4 (7%) had <11 mg/dL. When com-
pared with 193 febrile patients with-
out Bartonella infection, the 57 Bar-
tonella-infected patients were similar 
in age and sex but were more likely to 
be rice farmers and were more likely 
to have leukocytosis (Table). Com-
pared with the 70 nonfebrile controls, 
Bartonella-infected case-patients 
were more likely to report tick ex-
posure (32% vs. 7.9%; AOR = 5.6, 
95% CI 1.5–21) and outdoor activi-
ties (55% vs. 31%; AOR = 2.7, 95% 
CI 1.0–7.4) during the 2 weeks before 
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